Compound Summary
Compound Information
losartan
Compound Name: | losartan |
Compound CID: | 3961 |
Synonyms: | losartan 114798-26-4 DUP 89 Lortaan Cozaar More... |
Iupac Name: | [2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol |
InChI: | InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28) |
InChIKey: | PSIFNNKUMBGKDQ-UHFFFAOYSA-N |
Canonical Smiles: | CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl |
Isomeric Smiles: | CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl |
Molecular Weight: | 422.9 |
Molecular Formula: | C22H23ClN6O |
Compound Structure
2D Structure:
3D Structure:
Computed Properties
losartan
Molecular Weight: | 422.9 |
Molecular Formula: | C22H23ClN6O |
Hydrogen Bond Donor Count: | 2 |
Hydrogen Bond Acceptor Count: | 5 |
Rotatable Bond Count: | 8 |
Heavy Atom Count: | 30 |
Complexity: | 520 |
Synonyms
losartan
| losartan | losartan |
|---|---|
losartan |
114798-26-4 |
DUP 89 |
Lortaan |
Cozaar |
LOSARTAN POTASSIUM |
Hyzaar |
UNII-JMS50MPO89 |
DuP-753 |
CHEBI:6541 |
MK-954 |
JMS50MPO89 |
(2-butyl-4-chloro-1-{2-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl}-1H-imidazol-5-yl)methanol |
2-butyl-5-chloro-3-4-2-(2H-tetrazol-5-yl)phenylphenylmethylimidazol-4-ylmethanol |
2-n-butyl-4-chloro-5-hydroxymethyl-1-(2-(1H-tetrazol-5-yl)biphenyl-4-yl)methylimidazole |
DTXSID7023227 |
DuP 753 |
MFCD00865831 |
(1-((2-(2H-tetrazol-5-yl)-1,1-biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol |
NCGC00095125-01 |
Losartan INN:BAN |
DSSTox_CID_3227 |
DSSTox_RID_76933 |
DSSTox_GSID_23227 |
(1-((2-(1H-tetrazol-5-yl)-1,1-biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol" |
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-((2-(1H-tetrazol-5-yl)(1,1- biphenyl)-4-yl)methyl)- |
C22H23ClN6O |
(1-((2-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1H-imidazol-5-yl)methanol |
3Hlosartan |
Losartan (INN) |
Losartic (TN) |
2-butyl-5-chloranyl-3-4-2-(2H-1,2,3,4-tetrazol-5-yl)phenylphenylmethylimidazol-4-ylmethanol |
1H-imidazole-5-methanol, 2-butyl-4-chloro-1-2-(2H-tetrazol-5-yl)1,1-biphenyl-4-ylmethyl-" |
2-BUTYL-4-CHLORO-1-2-(1H-TETRAZOL-5-YL)1,1-BIPHENYL-4-YLMETHYL-1H-IMIDAZOLE-5-METHANOL |
3H-losartan |
CAS-114798-26-4 |
SR-01000763170 |
lorastan |
2-Butyl-4-chloro-1-((2-(1H-etrazol-5-yl) (1,1-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol |
2-butyl-5-chloro-3-4-2-(1H-tetrazol-5-yl)phenylphenylmethylimidazol-4-ylmethanol |
Dup89 |
Spectrum_001713 |
SCHEMBL60 |
Spectrum2_001677 |
Spectrum3_000998 |
Spectrum4_001126 |
Spectrum5_001466 |
Epitope ID:140137 |
EC 601-329-8 |
Oprea1_644635 |
US9624243, Losartin |
BSPBio_002695 |
GTPL590 |
KBioGR_001611 |
KBioSS_002193 |
(2-butyl-4-chloro-1-{2-(1H-tetrazol-5-yl)1,1-biphenyl-4-ylmethyl}-1H-imidazol-5-yl)methanol |
BIDD:GT0286 |
SPECTRUM1504268 |
SPBio_001893 |
DUP-89 |
GTPL3941 |
BDBM82258 |
HSDB 7043 |
KBio2_002193 |
KBio2_004761 |
KBio2_007329 |
KBio3_001915 |
HGP1405 |
BCPP000183 |
BDBM318822 |
EX 89 |
HMS1922J13 |
HMS2093E22 |
HMS3715L11 |
Pharmakon1600-01504268 |
BCP27731 |
HGP-1405 |
NSC_3961 |
ZINC3873160 |
Tox21_111435 |
CCG-39095 |
NSC758699 |
s5067 |
STL419984 |
2-butyl-4-chloro-1-p-(o-1H-tetrazol-5ylphenyl)benzylimidazole-5-methanol |
AKOS015917390 |
AKOS015994740 |
Tox21_111435_1 |
AB07507 |
BCP9000861 |
DB00678 |
KS-5004 |
MCULE-5204931675 |
NSC 758699 |
NSC-758699 |
(2-butyl-4-chloro-1-{2-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl}-1H-imidazol-5-yl)methanol" |
2-n-butyl-4-chloro-5-hydroxymethyl-1-2-(1H-tetrazol-5-yl)-biphenyl-4-ylmethylimidazole |
NCGC00095125-02 |
NCGC00095125-03 |
NCGC00095125-05 |
NCGC00095125-08 |
NCGC00095125-15 |
2-butyl-4-chloro-1-({4-2-(2H-1,2,3,4-tetrazol-5-yl)phenylphenyl}methyl)-1H-imidazol-5-ylmethanol |
2-Butyl-4-chloro-1-2-(1H-tetrazol-5-yl)1,1-biphenyl-4-ylmethyl-1H-imidazole-5-methanol |
BL164640 |
HY-17512 |
I497 |
SBI-0206766.P001 |
AB0013723 |
CAS_114798-26-4 |
FT-0631074 |
C07072 |
D08146 |
54244-EP2269989A1 |
54244-EP2270011A1 |
54244-EP2272841A1 |
54244-EP2277879A1 |
54244-EP2287165A2 |
54244-EP2287166A2 |
54244-EP2292620A2 |
54244-EP2295053A1 |
54244-EP2295406A1 |
54244-EP2298772A1 |
54244-EP2298776A1 |
54244-EP2298779A1 |
54244-EP2301923A1 |
54244-EP2301931A1 |
54244-EP2301936A1 |
54244-EP2305219A1 |
54244-EP2308562A2 |
54244-EP2308839A1 |
AB01563296_01 |
798L264 |
A803239 |
L000351 |
Q410074 |
Q-201321 |
SR-01000763170-3 |
SR-01000763170-4 |
BRD-K76205745-001-02-5 |
BRD-K76205745-001-04-1 |
F2173-0506 |
2-butyl-4-chloro-5-hydroxymethyl-1-(2-(1H-tetrazol-5-yl)-biphenyl-4-yl)methylimidazole" |
2-butyl-4-chloro-5-hydroxymethyl-1-(2-(1H-tetrazol-5-yl)biphenyl-4-yl)methylimidazole" |
(1-((2-(2h-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-4-chloro-1h-imidazol-5-yl)methanol" |
{2-Butyl-5-chloro-3-2-(2H-tetrazol-5-yl)-biphenyl-4-ylmethyl-3H-imidazol-4-yl}-methanol" |
1H-Imidazole-5-methanol, 2-butyl-4-chloro-1-2-(1H-tetrazol-5-yl)1,1-biphenyl-4-ylmethyl- (9CI)" |
2-butyl-4-chloro-1-2-(2h-tetrazol-5-yl)1,1-biphenyl-4-ylmethyl-1h-imidazole-5-methanol" |
2-butyl-4-chloro-1-2-(2H-tetrazol-5-yl)-1,1-biphenyl-4-ylmethyl-1H- imidazole-5-methanol" |
2-butyl-4-chloro-5-(hydroxymethyl)-1-2-(1H-tetrazol-5-yl)biphenyl-4-ylmethylimidazole" |
Experimental Data
losartan
| Species | Dosage | Unit | CG Lifespan(AVG/MED days) | TG Lifespan(AVG/MED days) | Lifespan Change(AVG/MED%) | CG Lifespan(MAX days) | TG Lifespan(MAX days) | Lifespan Change(MAX%) | Significant | Strain | Gender | PubMed | Active Label |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rattus norvegicus | 30 | mg/kg | 735 | 877 | 0.19 | S | 17557916 | Active |
Experimental Data Visualization
losartan
Statistics Data
losartan
| Species | Lifespan Change(AVG/MED%) | Lifespan Change(MAX%) | Count Reference | Count Data point |
|---|---|---|---|---|
| Rattus norvegicus | 0.19 | 1 | 1 |
Statistics Data Visualization
losartan
